[50]
SUCCESSFUL LONG-TERM
TREATMENT OF PAIN IN POST-HERPETIC
NEURALGIA WITH THE VENOM OF APIS
MELLIFERA
*Andrew Kochan, M.D.
The
treatment of post-herpetic neuralgia
(PHN) is unsatisfactory to most
sufferers and strictly palliative
in nature. Current treatments involve
tedious repetitive procedures, or
the taking of medications that may
have serious side effects. None
of these interventions alter the
natural history of the condition.
Treating
pain with the venom of the European
honeybee, Apis mellifera, dates
back several thousand years. Eleven
PHN patients, who suffered pain
for an average of 45.5 months (range
6 to 131), were injected at multiple
sites (range 3 to 30) with 100 micrograms
of dried bee venom in 0.1 cc of
0.5% lidocaine. These sites corresponded
to the location of the greatest
pain, origins of shooting pain and
to areas of cutaneous scarring.
Patients received an average of
15 treatments.
The
mean Visual Analog Scale (VAS) pain
score at the beginning of treatment
was 7.8 ± 1.4 and at the
end was 2.7 ± 2.3, representing
a mean decrease of 4.8 ±
3.3 (p < 0.005). Within 3 days
of beginning treatment five patients
noted significant improvement (>50%
decrease in pain). At follow-up,
which averaged 18 months from completion
of treatment, the group had a mean
VAS score of 2.8 ± 2.8, with
3 of the patients pain-free. Initially,
9 patients were taking antidepressants
and 3 were taking opioids. By the
end of treatment, 5 patients stopped
antidepressants and 1 stopped opioids.
Those remaining on medication were
on lower dosages.
There
are over 20 biologically active
peptides in Apis mellifera venom,
some of which are anti-inflammatory
and others neurotoxic in nature.
The results of treatment in these
patients suggest that one or more
components of honeybee venom are
able to decrease the pain of PHN
by more than 66%. The results are
maintained long-term. Relief of
pain using bee venom may involve
retrograde transport of one or more
of these peptides in the axon of
the affected nerve cell to the DRG,
thereby modifying transmission of
the pain signal to the CNS.
Corresponding Author:
Andrew Kochan M.D., 8744 Paso Robles
Ave., Northridge, CA 91325, USA
©